The threshold at which low-level viremia (LLV) becomes predictive of disease progression varies between studies, although evidence shows that incomplete viral suppression leads to the accumulation ...

Memo Therapeutics (MTx) has completed patient enrolment for its US-based Phase II clinical trial of potravitug, a monoclonal ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call.

艾滋病是影响公众健康的重要公共卫生问题之一 [1] ，随着医学的飞速发展，艾滋病的治疗与管理步入一个全新的时代。2024年，我国艾滋病防治领域迎来了又一里程碑式的进展。 1985年报道我国 ...

The recent detection on an Oregon farm raises the risk of the influenza virus acquiring mutations that lead to a pandemic ...

PRESS RELEASEFrits is an industry veteran with a proven track record in nephrology drug development, including the successful development of ...

18 The primary outcome was adjusted for factors potentially associated with transplantation outcomes, including recipient hepatitis C viremia, treatment with antithymocyte globulin (ATG), and ...

However, there are studies demonstrating a link between slightly higher levels of viremia (i.e., ≥400 copies/mL) and clinical disease progression. For example, data from the SMART (Strategies ...

Memo Therapeutics AG (MTx), a late-stage biotech company translating unique immune responses into superior medicines to treat ...